Malaria vaccine allocation status. Vaccine allocation categories shown with color for each country are as follows: Allocated, countries allocated vaccine for phase 1 areas; Awaiting, countries approved for Gavi support for malaria vaccine allocation but currently without supply; Not approved, countries not approved for Gavi support for malaria vaccine allocation; Partial, countries allocated partial supply awaiting further supply; Pilot, countries allocated vaccines to continue in the WHO-coordinated vaccine piloting program (i.e., MVIP countries). These were determined based on proxy measures of malaria disease burden and of child risk of death. R21 status denotes country-level regulatory status of R21 vaccine. The presence of a black dot in each country indicates that R21 has been licensed in the country. Gavi-eligible countries Burkina Faso (allocated), Ghana (pilot), and Nigeria (not approved) have licensed R21. Nigeria and Tanzania, although being among the four countries that the World Malaria Reports 20222023 identified as having accounted for just over half of all malaria deaths in 20212022, were not approved for Gavi support for priority allocation for 20232025. Data sources: [ 1 , 6 , 8 , 9 , 10 ]
